Patents Examined by Bin Shen
  • Patent number: 11649477
    Abstract: Systems and methods for antimicrobial susceptibility testing (AST) are provided in which variances in anionic charge of microbes are taken into account. Cationic surfactants may be used to sensitize otherwise resistant microorganisms to polycationic antibiotics, such as polymyxins. Since microorganisms gain polycationic antibiotic resistance through mutations that decrease surface anionic charge, the susceptibility of a microorganism to a polycationic antibiotic may be indicative of its surface charge. In order to enable electrostatic interactions with the microorganism surface, a cationic surfactant may be applied to increase the anionic charge of the microorganism.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: May 16, 2023
    Assignee: SELUX DIAGNOSTICS, INC.
    Inventors: Benjamin Spears, Kelly Flentie
  • Patent number: 11649440
    Abstract: The present invention refers to Amadoriase enzyme protein variants having de-glycating activity and improved thermostability compared to the wild type Amadoriase. The present invention refers also to the use of the thermostabilized Amadoriase as deglycating agent, preferably in the food industry. Moreover, the present invention refers to the use of the thermostabilized Amadoriase as diagnostic and/or therapeutic tools. Preferably, the Amadoriase enzyme protein variants of the invention can be used for determining the level of glycated haemoglobin in a biological sample and therefore for monitoring diabetes.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: May 16, 2023
    Assignees: FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA, POLITECNICO DI MILANO
    Inventors: Alfonso Gautieri, Emilio Parisini, Federica Rigoldi, Stefano Donini, Alberto Redaelli
  • Patent number: 11603515
    Abstract: [Problem] An object of the present invention is to produce cancer cell clusters with intrinsic biological properties as cancer tissues, such as morphological polarity and tissue motion polarity, in vitro. [Solution] The present invention relates to a cell culture substrate including a base material and a biocompatible polymer layer, the substrate including a plurality of rough sections on the surface of the substrate, wherein the rough sections are not covered with the biocompatible polymer layer, have a predetermined surface structure with a predetermined shape, and are disposed at predetermined intervals. With the present invention, it is possible to obtain a live cancer cell aggregate having morphological polarity and tissue motion polarity similar to that observed in vivo, by a very easy operation of culturing cancer cells on a cell culture substrate having a predetermined structure, thereby performing live imaging of microtumors in vitro is enabled, which has been conventionally impossible.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: March 14, 2023
    Assignee: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Yukiko Miyatake, Kaori Shigetomi, Takaharu Okajima, Masanori Kasahara
  • Patent number: 11567075
    Abstract: According to an immunochromatographic device for detecting a substance to be detected contained in a detection target in an analyte which is characterized in that a nitrous acid compound containing member having a part containing a nitrous acid compound; a labeling substance retaining member having a labeling substance containing part; an acid anhydride containing member having a part containing an acid anhydride having vapor pressure at 25° C. of 5×10?2 Pa or less; and a chromatography medium member having a detection part are arranged in a manner that a sample develops in the members in this order, the storage stability can be improved; detection with high sensitivity is possible; and the complexity of production can be reduced.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: January 31, 2023
    Assignee: TANAKA KIKINZOKU KOGYO K.K.
    Inventors: Hiroshi Kishi, Hiroko Mochizuki
  • Patent number: 11561179
    Abstract: Microscopic analysis of a sample includes a fluorescent dye disposed within the sample. A mid-IR optical source generates a mid-infrared beam, which is directed onto the sample to induce a temperature change by absorption of the mid-infrared beam. An optical source generates a probe beam directed to impinge on the sample. A detector detects fluorescent emissions from the sample when the probe beam impinges on the sample. A data acquisition and processing system acquires and processes the detected fluorescent emissions from the sample to: (i) generate a signal indicative of infrared absorption by the sample, (ii) generate a signal indicative of temperature in the sample based on the signal indicative of infrared absorption by the sample, (iii) generate an image of the sample using the signal indicative of temperature in the sample.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: January 24, 2023
    Assignee: Trustees of Boston University
    Inventors: Ji-Xin Cheng, Yi Zhang, Cheng Zong
  • Patent number: 11506654
    Abstract: A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: November 22, 2022
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Byung Hwa Jung, Hyun Beom Lee, Naeun Yoon
  • Patent number: 11492652
    Abstract: A method of assessing a possibility of cancerization including culturing a cell structure including normal cells and having a vascular network structure in a presence of a biological specimen from a subject, and assessing a possibility of cancerization in the subject based on a state of vessels in the cell structure after the culturing. The biological specimen is a body fluid specimen from the subject, a cell extract of cells from the subject, or a culture supernatant of cells from the subject, and the possibility of cancerization is assessed as high in the subject when a number of cells forming the vessels in the cell structure is larger than a number of cells cultured in an absence of the body fluid specimen, or when the vascular network structure in the cell structure extends.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: November 8, 2022
    Assignee: TOPPAN PRINTING CO., LTD.
    Inventors: Shiro Kitano, Kei Tsukamoto, Shinji Irie
  • Patent number: 11484624
    Abstract: A method for coating a solid surface with a recombinant spider silk protein capable of forming polymeric, solid structures is provided. The method is comprising the following steps: exposing the solid surface to an aqueous solution of the recombinant spider silk protein and thereby forming a surface layer of the recombinant spider silk protein adsorbed on the solid surface without formation of covalent bonds between the recombinant spider silk protein and the solid surface; and further exposing the surface layer of the solid surface to an aqueous solution of the recombinant spider silk protein and thereby forming an assembled silk structure layer of the recombinant spider silk protein on the surface layer; wherein the method does not include drying-in of spider silk protein.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: November 1, 2022
    Assignee: SPIBER TECHNOLOGIES AB
    Inventors: My Hedhammar, Linnea Nilebäck
  • Patent number: 11477981
    Abstract: This disclosure relates to ice nucleation formulations for cryopreservation and stabilization of biologics, and methods of use thereof.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 25, 2022
    Assignee: The General Hospital Corporation
    Inventors: Mehmet Toner, Shannon N. Tessier, Lindong Weng, Shannon L. Stott
  • Patent number: 11480572
    Abstract: Systems and methods for predicting an immune response against a tumor in a patient having the tumor are provided. The relative mass or changes of mass of tumor cells or immune cell in the tumor can be ex vivo observed, and an immune status of the tumor can be determined based on the mass of tumor cells or immune cell. The immune status can provide a guidance to predict the immune response against the tumor in the patient.
    Type: Grant
    Filed: December 17, 2017
    Date of Patent: October 25, 2022
    Assignees: NantBio, Inc., Nant Holdings IP, LLP
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Nicholas J. Witchey
  • Patent number: 11453858
    Abstract: In some aspects, described herein are cell culture media that are useful for in vitro culture of mammalian cells. The culture media contain a variety of small organic compounds that are found in normal adult human blood. Also described are methods of using the culture media for a variety of purposes. Also described are methods of treating cancer.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: September 27, 2022
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: David M. Sabatini, Jason Cantor
  • Patent number: 11448645
    Abstract: Cultivation and/or test-system comprising at least two cultivation spaces combined in a microparticle, wherein the sperically shaped microparticle comprises, (i) a first cultivation space in the center core of said spherically shaped microparticle, (ii) a second cultivation space in the wall surrounding the core of said microparticle, (iii) wherein the wall surrounding the core allows for the exchange of molecules as, salts, nutrients, peptides, chemicals and other compounds in order for the cells in the first cultivation space to interact with the cells in second cultivation space and vice versa. In the test system, the cells are co-cultivated and the microparticles are then selected based on the phenotype of the cells in the first or second cultivation space.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: September 20, 2022
    Assignee: Biomillenia SAS
    Inventors: Dirk Loeffert, Aleksander Dajkovic, Thomas Duboys
  • Patent number: 11447638
    Abstract: The present invention provides di-substituted acetalanthraquinone-based compounds of the Formulae (l)-(IV) that are useful for cellular staining and for light-based detection of biological material, e.g. fluorescence-based detection of biological material. These compounds may be used in hydrolysed or non-hydrolysed form. Also provided is a fluorescent complex that comprises a nucleic acid and an acetalanthraquinone-based compound of the invention; and a method of staining a biological sample comprising cells or other biological material containing nucleic acid, which method comprises contacting the biological sample with an acetalanthraquinone-based compound of the invention. In the Formulae (l)-(IV), A and B are each independently of formula —RaCH2CH(ORb)2; or one of A and B is of formula —RaCH2CH(ORb)2 and the other one is of formula: —NRb2.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 20, 2022
    Assignee: BIOSTATUS LIMITED
    Inventors: Paul James Smith, Rachel Jane Errington, Laurence Hylton Patterson, Klaus Pors, Laura Cosentino
  • Patent number: 11442072
    Abstract: The present disclosure relates to a method for measuring aggregation of low-density lipoprotein (LDL). The susceptibility of LDL to aggregate is an important factor regarding prognosis, diagnosis and surveillance of atherosclerotic cardiovascular diseases and cardiometabolic diseases, such as type 2 diabetes and related conditions, at various stages of their development. Also provided are methods of treatment of such diseases in subjects in need thereof.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 13, 2022
    Assignee: Jenny and Antti Wihuri Foundation
    Inventors: Katariina Öörni, Maija Ruuth, Petri Kovanen
  • Patent number: 11442063
    Abstract: Provided herein are compounds that are broad-spectrum protein kinase binding agents, detectable tracers comprising such compounds, and method of use thereof for the detection of protein kinases.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: September 13, 2022
    Assignee: Promega Corporation
    Inventors: Cesear Corona, Poncho Meisenheimer, Matthew Robers, James Vasta
  • Patent number: 11439691
    Abstract: The present invention relates to an aqueous solution comprising burlulipase which is characterized in that it contains calcium ions. In particular, it also relates to corresponding pharmaceuticals. Such pharmaceuticals are suitable for the treatment of exocrine pancreatic insufficiency. These pharmaceuticals are particularly suitable for treating patients having cystic fibrosis and in pediatrics. Another aspect of the present invention relates to container-packaged solutions and pharmaceuticals as mentioned above, which are containers produced by the blow-fill-seal method, and to methods for producing such packaged solutions and pharmaceuticals.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: September 13, 2022
    Assignee: NORDMARK PHARMA GMBH
    Inventors: Richard Fuhrherr, Annika Müller-Lucks, Katharina Rützel, Jan Lüdemann, Martin Werner
  • Patent number: 11419830
    Abstract: The present invention is directed, in part, to methods of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of a of Coenzyme Q10 (CoQ10) to the subject.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: August 23, 2022
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, Rangaprasad Sarangarajan, Michael Andrew Kiebish
  • Patent number: 11414691
    Abstract: Provided are an organoid having a metastatic property when transplanted into an immunocompetent non-human animal of the same species, a cell strain having a metastatic property when transplanted into an immunocompetent non-human animal of the same species, and a non-human animal including the organoid or the cell strain.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: August 16, 2022
    Assignee: National University Corporation Kanazawa University
    Inventors: Masanobu Oshima, Mizuho Nakayama, Eri Sakai
  • Patent number: 11401501
    Abstract: The present invention provides a method for culturing organoids, the method comprising: a) disassociating unprocessed organoids to produce a cell suspension; b) sieving the cell suspension through a cell strainer to retain a sieved cell suspension containing cells of about 10 ?m to about 1 mm in diameter; and c) seeding cells of the sieved cell suspension into a bioreactor in a cell culture medium comprising an extracellular support matrix.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: August 2, 2022
    Assignee: CELLESCE LIMITED
    Inventors: Marianne J. Ellis, Julian Chaudhuri, Trevor Clive Dale
  • Patent number: 11401502
    Abstract: An object of the present invention is to provide highly proliferative mesenchymal stem cells (MSCs) useful for the large-scale and rapid production of a cell preparation, and a cell population comprising the mesenchymal stem cells. According to the present invention, there is provided a cell population comprising mesenchymal stem cells derived from the fetal appendage, wherein, in the cell population, the proportion of CD105+ mesenchymal stem cells is 50% or more, the proportion of CD200+ mesenchymal stem cells is less than 10%, and the proportion of CD106+ mesenchymal stem cells is less than 5%.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: August 2, 2022
    Assignee: KANEKA CORPORATION
    Inventors: Masahiro Hayashi, Yuta Kita, Nobuyoshi Umeda